Eli Lilly's Oral Weight-Loss Pill Foundayo Wins First European Approval in the UK

Britain's Medicines and Healthcare products Regulatory Agency approved Eli Lilly's oral GLP-1 pill orforglipron, branded Foundayo, on August 10, making the UK the first European country to clear the drug for both weight management and Type 2 diabetes. The approval extends Foundayo's commercial reach beyond the United States, where it launched earlier in 2026 after receiving FDA clearance. Lilly faces direct competition from Novo Nordisk, whose oral Wegovy pill had already secured British approval ahead of Foundayo, meaning Novo beat Lilly to market in the UK for an oral obesity therapy.

Shares of Eli Lilly rose 2.1% on the news. A Barron's column published the same day also flagged Lilly alongside Nvidia and Disney as a company investors should favor in the current risk-averse environment, where the market is rewarding proven large-cap winners.